Jason Luke, MD, FACP

Jason Luke, MD, FACP, associate professor of medicine in the Division of Hematology/Oncology and the director of the Cancer Immunotherapeutic Center at the UPMC Hillman Cancer Center, discusses promising clinical research around intratumoral immunotherapy.

There are multiple studies in the area of intratumoral immunotherapy that have the potential to make a large impact in the field, says Luke. One notable trail is a randomized phase III, which is evaluating tilsotolimod with or against ipilimumab (Yervoy) in patients with melanoma. If the trial is positive, it may impact the standard of car, by offering a new option for patients with melanoma who progress on a PD-1 inhibitor.

Videos

Jason Luke, MD, FACP, discusses promising clinical research around intratumoral immunotherapy.

Exploring Intratumoral Immunotherapy in Melanoma and Other Malignancies

Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the international MSLT-II trial, which looks at the possibility of less surgery for melanoma patients in the future.

Luke says the trial is investigating lymph nodes and how medical professionals are diagnosing tumors. He adds that while a lymph node may come up positive for melanoma, the test may only be showing one cancerous cell that could be taken out without as much surgery.

Jason Luke, MD, FACP | Authors

Articles

Exploring Intratumoral Immunotherapy in Melanoma and Other Malignancies

Dr. Jason Luke on Advances in How Melanoma is Diagnosed